Table 1.
Associations between ERβ1 expression and clinicopathological factors in female ERα‐negative PTC tissue specimens
| Patient characteristics | Positive percentage | P‐value | Total scorea | P‐value | Subcellular localization | P‐value | ||
|---|---|---|---|---|---|---|---|---|
| Nu | Nu+Cyto | Cyto | ||||||
| Age at diagnosis (years) | ||||||||
| <55 (n = 47) | 46 (97.9) | 0.250 | 5.98 ± 1.50 | 0.841 | 9 (19.6) | 30 (65.2) | 7 (15.2) | 0.564 |
| ≥55 (n = 23) | 21 (91.3) | 5.70 ± 2.08 | 2 (9.5) | 16 (76.2) | 3 (14.3) | |||
| Menopausal status | ||||||||
| Pre (n = 33) | 32 (97.0) | 1.000 | 5.85 ± 1.52 | 0.580 | 6 (18.8) | 20 (62.5) | 6 (18.8) | 0.565 |
| Post (n = 37) | 35 (94.6) | 5.92 ± 1.86 | 5 (14.3) | 26 (74.3) | 4 (11.4) | |||
| Tumour size (cm) | ||||||||
| ≤20 mm (n = 45) | 44 (97.8) | 0.289 | 6.04 ± 1.46 | 0.410 | 10 (22.7) | 29 (65.9) | 5 (11.4) | 0.114 |
| >20 mm (n = 25) | 23 (92.0) | 5.60 ± 2.06 | 1 (4.3) | 17 (73.9) | 5 (21.7) | |||
| LNM | ||||||||
| − (n = 40) | 38 (95.0) | 1.000 | 6.25 ± 1.69 | 0.003 | 6 (15.8) | 28 (73.7) | 4 (10.5) | 0.476 |
| + (n = 30) | 29 (96.7) | 5.40 ± 1.61 | 5 (17.2) | 18 (62.1) | 6 (20.7) | |||
| ETE | ||||||||
| − (n = 47) | 45 (95.7) | 1.000 | 6.23 ± 1.64 | 0.001 | 9 (20.0) | 31 (68.9) | 5 (11.1) | 0.300 |
| + (n = 23) | 22 (95.7) | 5.17 ± 1.61 | 2 (9.1) | 15 (68.2) | 5 (22.7) | |||
| TNM stage | ||||||||
| I/II (n = 60) | 58 (96.7) | 0.375 | 5.97 ± 1.63 | 0.293 | 10 (17.2) | 39 (67.2) | 9 (15.5) | 0.816 |
| III/IV (n = 10) | 9 (90.0) | 5.40 ± 2.12 | 1 (11.1) | 7 (77.8) | 1 (11.1) | |||
PTC, papillary thyroid cancer; LNM, lymph node metastases; ETE, extrathyroidal extension; TNM stage, tumour node metastasis stage; n, number of patients. Nu, exclusively nuclear staining; Nu + Cyto, combined nuclear and cytoplasmic staining; Cyto, exclusively cytoplasmic staining.
a
Total score was calculated from the sum of the proportion staining score and intensity score to reflect the expression level, which is given as the mean ± S.D.